Find A Clinical Trial

Disease Type: Multiple Myeloma

Trial ID USOR 18126
Sponsor ID Seattle Genetics, Inc

A Phase 1 Study of SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

Principal Investigator
Mitul Gandhi, MD
Trial ID USOR 20285
Sponsor ID Karyopharm Therapeutics

A Phase 2 Trial of Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Combination with Selinexor For Patients with Newly Diagnosed Multiple Myeloma

Principal Investigator
Mitul Gandhi, MD
4 Locations
Trial ID 19247
Sponsor ID Janssen

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Principal Investigator
Mitul Gandhi, MD
5 Locations
Trial ID 18-255-02
Sponsor ID Nektar Therapeutics

A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-255 AS A SINGLE AGENT IN RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES AND IN COMBINATION WITH DARATUMUMAB AS A SALVAGE REGIMEN FOR MULTIPLE MYELOMA

Principal Investigator
Gregory J. Orloff, MD
Trial ID 19064
Sponsor ID

A PHASE Ia/Ib OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF TIRAGOLUMAB AS A SINGLE AGENT AND IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA, AND AS A SINGLE AGENT AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.(GO41036)

Principal Investigator
Gregory J. Orloff, MD